The biotech industry needs to stop waiting for a rebound. The pandemic changed everything, though not in the ways most people ...
The multivalent candidate, being developed by Pfizer and French partner Valneva under a 2020 pact, generated higher than 73% ...
The FDA detected 14 cases of vitamin B6 deficiency–linked seizures and two deaths in patients with Parkinson’s disease taking ...
That’s not for lack of opportunity. Japan’s scientists continue to produce Nobel Prize–winning breakthroughs and the country ...
Healthcare investor Kevin Tang and his allies now hold almost every leadership position at Aurinia Pharmaceuticals, the ...
Oryon Cell Therapies’ lead cell therapy is an autologous treatment designed to replace dopaminergic neurons in patients with ...
Earendil Labs’ AI-centered platform has produced more than 40 programs, including anti-inflammatory assets that have attracted a pair of partnership agreements with Sanofi.
Eli Lilly and Regeneron are leading the push to treat congenital deafness with gene therapies, seeking a piece of a potential ...
The FDA’s Commissioner’s National Priority Voucher program, unveiled in June 2025, is “shrouded in secrecy,” Democratic ...
Longevity is a long-standing buzzword in life sciences, but it now has staying power. The smart trajectory is to stop chasing ...
As cell therapy advances toward clinical reality, iPSC-derived cellular products, in vivo reprogramming strategies, and ...
As Congress debates renewing the Act for ALS, it must prepare for the coming era of precision ALS medicine by prioritizing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results